| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20000787 | HPV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS20010614 | HPV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS20006685 | HPV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS20062059 | HPV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS20062240 | HPV | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS44033258 | HTLV-1 | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS44016804 | HTLV-1 | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS44015123 | HTLV-1 | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
| TVIS44012059 | HTLV-1 | ENSG00000146648.21 | protein_coding | EGFR | Yes | No | 1956 | E7BSV0 P00533 Q504U8 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EGFR |
|---|---|
| DrugBank ID | DB01269 |
| Drug Name | Panitumumab |
| Target ID | BE0000767 |
| UniProt ID | P00533 |
| Regulation Type | suppressor |
| PubMed IDs | 11894013; 12620146; 14967460; 16012181; 16857825; 11255078; 20623992; 18343240; 17355997; 18503402; 20481659; 11752352 |
| Citations | Lynch DH, Yang XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002 Feb;29(1 Suppl 4):47-50.@@Cohen RB: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003 Feb;2(4):246-51.@@Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90.@@Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005 Sep;16(9):1425-33. Epub 2005 Jul 12.@@Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R: Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s.@@Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23.@@Keating GM: Spotlight on panitumumab in metastatic colorectal cancer. BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000.@@Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014.@@Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13.@@Jean GW, Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.@@Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | Panitumumab Action Pathway |
| PharmGKB | PA162373091 |
| ChEMBL | CHEMBL1201827 |
